Claims

1. A heterodimeric fusion comprising:

    (i) a polypeptide according to SEQ ID NO: 11; and

    (ii) a polypeptide according to SEQ ID NO: 20,

wherein SEQ ID NO: 11 comprises a first heterodimerisation domain connected to a Relaxin A chain polypeptide;

wherein SEQ ID NO: 20 comprises a second heterodimerisation domain connected to a Relaxin B chain polypeptide;

wherein the first heterodimerisation domain heterodimerises with the second heterodimerisation domain, and wherein the heterodimeric fusion has Relaxin activity.

2. The heterodimeric fusion according to Claim 1, wherein the Relaxin A chain polypeptide and the Relaxin B chain polypeptide are covalently bound by at least one inter-chain disulphide bond.

3. The heterodimeric fusion according to Claim 1 or 2, wherein the Relaxin A chain and the Relaxin B chain are not covalently linked to each other by an amino acid linker.

4. A nucleic acid molecule encoding a heterodimeric fusion of any one of the preceding claims.

5. A vector comprising the nucleic acid molecule of Claim 4.

6. A host cell comprising the vector of Claim 5 or the nucleic acid molecule of Claim 4.

7. A method of producing the heterodimeric fusion of any one of Claims 1 to 3, the method comprising culturing the host cell of Claim 6 and collecting the fusion protein.

8. A pharmaceutical composition comprising the heterodimeric fusion of any one of Claims 1 to 3 and a pharmaceutically acceptable excipient.

9. A kit comprising the pharmaceutical composition of Claim 8.